Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources
News and Community
About us

Fresenius Kabi Australia Pty Ltd

Regulatory activities for this sponsor.

Loading...

ARTG (291) ARTG (291)
Cancellation by sponsor (126) Cancellation by sponsor (126)
Prescription medicine registration (13)
Australian Public Assessment Report (AusPAR) (6)
Prescription medicine decision summary (2)

2025 (2) 2025 (2)
2024 (50) 2024 (50)
2023 (45) 2023 (45)
2022 (29) 2022 (29)
2021 (13) 2021 (13)
2020 (31) 2020 (31)
2019 (59) 2019 (59)
2018 (17) 2018 (17)
2017 (14) 2017 (14)
2016 (18) 2016 (18)
2015 (23) 2015 (23)
2014 (8) 2014 (8)
2013 (26) 2013 (26)
2012 (18) 2012 (18)
2011 (5) 2011 (5)
2010 (5) 2010 (5)
2009 (1) 2009 (1)
2008 (13) 2008 (13)
2007 (13) 2007 (13)
2006 (26) 2006 (26)
2002 (2) 2002 (2)
2001 (3) 2001 (3)
1994 (7) 1994 (7)
1992 (3) 1992 (3)
1991 (7) 1991 (7)

Search

Sponsor content

438 result(s) found, displaying 41 to 50

FRESOFOL 1% propofol 500mg/50mL injection vial Cancelled under Section 30(1)(c) of the Act

24 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
FRESOFOL 1% propofol 200mg/20mL injection ampoule Cancelled under Section 30(1)(c) of the Act

24 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
KABIVEN G 11% 2400mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
KABIVEN G 11% 1920mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
KABIVEN G 19% 1026mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
GLAMIN amino acids/dipeptides 1000mL intravenous infusion injection bottle Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 333mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 30% 250mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
INTRALIPID 10% 500mL injection bag Cancelled under Section 30(1)(c) of the Act

13 June 2024

Cancellation by sponsor

Requested by Fresenius Kabi Australia Pty Ltd
Fresenius Kabi Australia Pty Ltd - Needle, subcutaneous injection/infusion port (431791)

22 December 2023

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Fresenius Kabi Australia Pty Ltd - Needle, subcutaneous injection/infusion port.

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve this page

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control - external site
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook - external site
(formerly Twitter) - external site
Youtube - external site
Instagram - external site
LinkedIn - external site

Help us improve

We are always looking for ways to improve our website.

Provide feedback - external site

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Fresenius Kabi Australia Pty Ltd

Type

Date

Help us improve this page